Takeda fiscal 2014 results in line with guidance

15 May 2015

Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502) has posted fiscal 2014 (year ended March 31, 29015) financial results in line with guidance. With underlying revenue growth of 2.8% to 1,691.7 billion yen ($14.09 billion) and underlying core earnings -2.1% to 314.2 billion yen, Takeda met its operational guidance for FY2014.

Reported revenue grew by 5.1% to 1,777.8 billion yen. The booking of a $2.7 billion provision to cover the Actos (pioglitazone) settlement and estimated costs associated with remaining cases and other related litigations, along with other one-time exceptional items, impacted operating profit (a loss of 129.3 billion yen), net profit (-145.8 billion yen) and earnings per share (-185 yen).

Back to profitable growth from FY2015

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK